Physician profile
Ryan David Poling
NPI 1558717835
$762.46
in general payments reported to CMS, 2019-2025
12 companies · $69.22 in 2025
The $69.22 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.04 · 2020: $199 · 2021: $125 · 2022: $263 · 2023: $17.21 · 2025: $69.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $86.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $86.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $169.98 | 2019-2022 | |
| Abbvie INC. | $150.83 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $150.76 | 2020-2022 | |
| Allergan, INC. | $55.49 | 2020 | |
| Pfizer INC. | $49.96 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $33.55 | 2022 | |
| Merck Sharp & Dohme LLC | $30.08 | 2020-2025 | Verquvo |
| Amgen INC. | $28.61 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.25 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.19 | 2019 | |
| Clovis Oncology, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Poling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.